| #1 | Cortico-Striatal Synchrony Restoration via NMDA Modulation | GRIN2B | 0.950 | $0.53 | SDA-2026-04-03-26abc |
| #2 | Gamma entrainment therapy to restore hippocampal-cortical synchrony | SST | 0.946 | $0.60 | SDA-2026-04-03-26abc |
| #3 | Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation | HCRTR1/HCRTR2 | 0.882 | $0.61 | sda-2026-04-01-gap-v |
| #4 | H6: Aberrant eIF2α Phosphorylation Creates Stalled Translation State | EIF2S1, EIF2AK3/PERK, PPP1R15B, EIF2B | 0.856 | $0.62 | SDA-2026-04-06-gap-p |
| #5 | TYROBP (DAP12) Conditional Antagonism for Early-Stage Neuroprotection | TYROBP | 0.844 | $0.65 | SDA-BIOMNI-GENE_COE- |
| #6 | Exposed amyloidogenic segments (β-sheet propensity residues) serve as HSP70 recognition codes | HSPA8, HSPA1A, DNAJB6, DNAJB2 | 0.840 | $0.64 | SDA-2026-04-10-gap-d |
| #7 | Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Prevents the Self-Amplifying Iron-Ferroptosis-Edema Cascade Post-Cardiac Arrest | Labile iron pool (deferoxamine target) and GPX4 (sulforaphane target) | 0.838 | $0.60 | SDA-2026-04-26-gap-p |
| #8 | AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses | PRKAA1 | 0.833 | $0.73 | sda-2026-04-01-gap-v |
| #9 | Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Aggregates Drives Non-Cell-Autonomous Neurodegeneration | NLRP3, CASP1, IL1B, PYCARD | 0.822 | $0.60 | SDA-2026-04-01-gap-2 |
| #10 | CSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion | CSF1R-TREM2 | 0.808 | $0.61 | SDA-2026-04-01-gap-0 |
| #11 | Neutrophil Extracellular Trap (NET) Inhibition | PADI4 | 0.806 | $0.69 | SDA-2026-04-16-gap-b |
| #12 | Targeted Butyrate Supplementation for Microglial Phenotype Modulation | GPR109A | 0.805 | $0.58 | SDA-2026-04-01-gap-2 |
| #13 | Dual-Receptor Antibody Shuttling | - | 0.803 | $0.60 | - |
| #14 | Hypothesis 1: MANF/CDNF Signaling as Primary Neuroprotective Effector | MANF, CDNF | 0.798 | $0.59 | SDA-2026-04-26-gap-p |
| #15 | Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs) | APOE | 0.795 | $0.59 | sda-2026-04-01-gap-0 |
| #16 | NMN Supplementation Restores SIRT1/p66Shc/FOXO3 Epigenetic Axis and Dopaminergic Neuron Survival in Parkinson's Disease Models | SIRT1/NAD+ axis | 0.790 | $0.60 | SDA-2026-04-04-gap-2 |
| #17 | Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Priming | TLR4 | 0.789 | $0.68 | SDA-2026-04-01-gap-2 |
| #18 | Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbates Amyloid Pathology | CHRNA7 (α7 nicotinic receptor), BACE1 | 0.785 | $0.60 | SDA-2026-04-12-20260 |
| #19 | Competitive APOE4 Domain Stabilization Peptides | APOE | 0.784 | $0.60 | sda-2026-04-01-gap-0 |
| #20 | SASP-Driven Aquaporin-4 Dysregulation | AQP4 | 0.782 | $0.64 | sda-2026-04-01-gap-0 |
| #21 | SIRT1/PGC-1α Axis Activation to Preserve Mitochondrial Resiliency Against Microbiome-Induced Neuroinflammation in PD | SIRT1, PGC-1α (PPARGC1A), NAMPT | 0.778 | $0.60 | SDA-BIOMNI-MICROBIO- |
| #22 | Transcriptional Autophagy-Lysosome Coupling | FOXO1 | 0.777 | $0.63 | sda-2026-04-01-gap-0 |
| #23 | Thalamocortical Synchrony Restoration via NMDA Modulation | GRIN2B | 0.774 | $0.56 | SDA-2026-04-03-26abc |
| #24 | Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation | FCGRT | 0.773 | $0.58 | sda-2026-04-01-gap-0 |
| #25 | Chromatin Accessibility Restoration via BRD4 Modulation | BRD4 | 0.768 | $0.60 | SDA-2026-04-04-gap-e |
| #26 | CYP46A1 Overexpression Gene Therapy | CYP46A1 | 0.768 | $0.65 | SDA-2026-04-01-gap-l |
| #27 | APOE4 Allosteric Rescue via Small Molecule Chaperones | APOE | 0.765 | $0.60 | sda-2026-04-01-gap-0 |
| #28 | SASP-Mediated Cholinergic Synapse Disruption | MMP2/MMP9 | 0.763 | $0.63 | sda-2026-04-01-gap-0 |
| #29 | Circadian Clock-Autophagy Synchronization | CLOCK | 0.763 | $0.59 | sda-2026-04-01-gap-v |
| #30 | Multi-Modal Stress Response Harmonization | NR3C1/CRH/TNFA | 0.756 | $0.57 | sda-2026-04-01-gap-0 |
| #31 | Senescence-Activated NAD+ Depletion Rescue | CD38/NAMPT | 0.755 | $0.57 | sda-2026-04-01-gap-0 |
| #32 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.755 | $0.59 | test-hypothesis-fixt |
| #33 | Temporal SPP1 Inhibition During Critical Windows | SPP1 | 0.752 | $0.67 | SDA-2026-04-15-gap-p |
| #34 | Dopaminergic Ventral Tegmental-Hippocampal Circuit Protection | MAPT | 0.751 | $0.57 | SDA-2026-04-03-26abc |
| #35 | Circadian-Synchronized Proteostasis Enhancement | CLOCK/ULK1 | 0.744 | $0.57 | sda-2026-04-01-gap-0 |
| #36 | Smartphone-Detected Motor Variability Correction | DRD2/SNCA | 0.742 | $0.58 | sda-2026-04-01-gap-0 |
| #37 | Senescent Cell Mitochondrial DNA Release | CGAS/STING1/DNASE2 | 0.742 | $0.58 | sda-2026-04-01-gap-0 |
| #38 | Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement | COX4I1 | 0.742 | $0.59 | sda-2026-04-01-gap-v |
| #39 | VPS35 retromer activation prevents endosomal tau templating across all brain regions and disease stages | VPS35 | 0.740 | $0.61 | SDA-2026-04-07-gap-d |
| #40 | PARP1 Inhibition Therapy | PARP1 | 0.738 | $0.63 | sda-2026-04-01-gap-0 |
| #41 | Senescence-Associated Myelin Lipid Remodeling | PLA2G6/PLA2G4A | 0.732 | $0.55 | sda-2026-04-01-gap-0 |
| #42 | Senescence-Induced Lipid Peroxidation Spreading | GPX4/SLC7A11 | 0.730 | $0.58 | sda-2026-04-01-gap-0 |
| #43 | Adenosine-Astrocyte Metabolic Reset | ADORA2A | 0.730 | $0.58 | sda-2026-04-01-gap-v |
| #44 | Phase-Separated Organelle Targeting | G3BP1 | 0.729 | $0.60 | sda-2026-04-01-gap-0 |
| #45 | TFEB/TFE3 Parallel Activation Drives Coordinated Organelle Clearance via CLEAR Network | TFEB (TFEB), TFE3 (TFE3), mTORC1 (MTOR) | 0.727 | $0.61 | SDA-2026-04-07-gap-p |
| #46 | Synthetic Biology BBB Endothelial Cell Reprogramming | TFR1, LRP1, CAV1, ABCB1 | 0.727 | $0.57 | sda-2026-04-01-gap-0 |
| #47 | Metabolic Switch Targeting for A1→A2 Repolarization | HK2 | 0.726 | $0.57 | sda-2026-04-01-gap-0 |
| #48 | Microglial TREM2-Complement Axis Modulation | TREM2 and C3 | 0.726 | $0.60 | SDA-2026-04-03-gap-s |
| #49 | TFAM overexpression creates mitochondrial donor-recipient gradients for directed organelle trafficking | TFAM | 0.725 | $0.59 | sda-2026-04-01-gap-v |
| #50 | Astrocyte-Mediated Neuronal Epigenetic Rescue | HDAC | 0.725 | $0.57 | SDA-2026-04-04-gap-e |
| #51 | Proteostasis Enhancement via APOE Chaperone Targeting | HSPA1A | 0.724 | $0.57 | sda-2026-04-01-gap-a |
| #52 | Interfacial Lipid Mimetics to Disrupt Domain Interaction | APOE | 0.723 | $0.58 | sda-2026-04-01-gap-0 |
| #53 | Circadian Rhythm Entrainment of Reactive Astrocytes | BMAL1 | 0.722 | $0.57 | sda-2026-04-01-gap-0 |
| #54 | Sleep Spindle-Synaptic Plasticity Enhancement | CACNA1G | 0.721 | $0.57 | sda-2026-04-01-gap-v |
| #55 | NLRP3 Inflammasome Lock Perpetuates Senescence-Associated Inflammasome Phenotype | NLRP3/CASP1/IL1B | 0.720 | $0.60 | SDA-2026-04-06-gap-p |
| #56 | Bacterial Curli Amyloid → Nucleation of α-Synuclein Misfolding in Enteric Neurons | CsgA, CsgB, CsgC, α-synuclein (SNCA) | 0.720 | $0.61 | sda-2026-04-01-gap-2 |
| #57 | Metabolic Reprogramming to Reverse Senescence | SIRT1,PGC1A,NAMPT | 0.720 | $0.61 | SDA-2026-04-04-gap-s |
| #58 | Magnetosonic-Triggered Transferrin Receptor Clustering | TFR1 | 0.719 | $0.57 | sda-2026-04-01-gap-0 |
| #59 | Retinal Vascular Microcirculation Rescue | PDGFRB/ANGPT1 | 0.718 | $0.57 | sda-2026-04-01-gap-0 |
| #60 | Circadian-Synchronized LRP1 Pathway Activation | LRP1, MTNR1A, MTNR1B | 0.714 | $0.56 | sda-2026-04-01-gap-0 |
| #61 | Purinergic Signaling Polarization Control | P2RY1 and P2RX7 | 0.713 | $0.58 | sda-2026-04-01-gap-0 |
| #62 | Circadian Glymphatic Rescue Therapy (Melatonin-focused) | MTNR1A | 0.712 | $0.56 | sda-2026-04-01-gap-v |
| #63 | Early Proteasome Restoration Therapy | PSMC | 0.712 | $0.56 | SDA-2026-04-03-gap-a |
| #64 | Noradrenergic-Tau Propagation Blockade | ADRA2A | 0.711 | $0.59 | sda-2026-04-01-gap-v |
| #65 | HDAC3-Selective Inhibition for Clock Reset | HDAC3 | 0.710 | $0.58 | sda-2026-04-01-gap-v |
| #66 | Autophagosome Maturation Checkpoint Control | STX17 | 0.709 | $0.60 | sda-2026-04-01-gap-0 |
| #67 | Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition | LOX/LOXL1-4 | 0.709 | $0.59 | sda-2026-04-01-gap-v |
| #68 | Orexin-Microglia Modulation Therapy | HCRTR2 | 0.707 | $0.60 | sda-2026-04-01-gap-v |
| #69 | TET2-Mediated Demethylation Rejuvenation Therapy | TET2 | 0.706 | $0.56 | sda-2026-04-01-gap-v |
| #70 | Lysosomal Enzyme Trafficking Correction | IGF2R | 0.706 | $0.60 | sda-2026-04-01-gap-0 |
| #71 | Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation | SDC1 | 0.705 | $0.58 | sda-2026-04-01-gap-v |
| #72 | Ferroptosis Inhibition for α-Synuclein Neuroprotection | GPX4 | 0.705 | $0.57 | SDA-2026-04-03-gap-a |
| #73 | Microglial Efferocytosis Enhancement via GPR32 Superagonists | CMKLR1 | 0.704 | $0.56 | sda-2026-04-01-gap-0 |
| #74 | TLR4/MyD88/NF-κB Axis Blockade to Interrupt LPS-Mediated Gut-Brain Neuroinflammation in PD | TLR4, MyD88 (MYD88), NF-κB (NFKB1) | 0.703 | $0.60 | SDA-2026-04-16-gap-2 |
| #75 | Purinergic P2Y12 Inverse Agonist Therapy | P2RY12 | 0.703 | $0.57 | sda-2026-04-01-gap-v |
| #76 | SCFA-Producing Bacterial Depletion → Loss of Neuroprotective Microenvironment | HDAC3, GPR41 (FFAR3), GPR43 (FFAR2), Nrf2, HMOX1 | 0.700 | $0.60 | sda-2026-04-01-gap-2 |
| #77 | Granzyme B Inhibition with Serpina3n to Preserve Axonal Integrity Against Cytotoxic Attack | GZMB | 0.698 | $0.60 | SDA-2026-04-15-gap-d |
| #78 | Lysosomal Calcium Channel Modulation Therapy | MCOLN1 | 0.697 | $0.58 | sda-2026-04-01-gap-0 |
| #79 | Axonal RNA Transport Reconstitution | HNRNPA2B1 | 0.695 | $0.58 | sda-2026-04-01-gap-v |
| #80 | Mitochondrial Transfer Pathway Enhancement | MIRO1 | 0.695 | $0.57 | sda-2026-04-01-gap-0 |
| #81 | Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy | ALOX15 | 0.695 | $0.56 | sda-2026-04-01-gap-0 |
| #82 | Palmitoylation-Targeted BACE1 Trafficking Disruptors | BACE1 | 0.693 | $0.55 | SDA-2026-04-01-gap-l |
| #83 | Ocular Immune Privilege Extension | FOXP3/TGFB1 | 0.692 | $0.56 | sda-2026-04-01-gap-0 |
| #84 | Sphingomyelin Synthase Activators for Raft Remodeling | SGMS1/SGMS2 | 0.692 | $0.56 | SDA-2026-04-01-gap-l |
| #85 | cGAS-STING Senescence Circuit Disruption | CGAS, STING1 | 0.691 | $0.58 | SDA-2026-04-03-gap-a |
| #86 | Extracellular Matrix Stiffness Modulation | PIEZO1 | 0.691 | $0.56 | sda-2026-04-01-gap-0 |
| #87 | Ganglioside Rebalancing Therapy | ST3GAL2/ST8SIA1 | 0.690 | $0.54 | SDA-2026-04-01-gap-l |
| #88 | Cross-Seeding Prevention Strategy | TARDBP | 0.689 | $0.58 | sda-2026-04-01-gap-v |
| #89 | Hypocretin-Neurogenesis Coupling Therapy | HCRT | 0.688 | $0.57 | sda-2026-04-01-gap-v |
| #90 | Wnt/β-catenin Pathway Restoration | CTNNB1 | 0.686 | $0.60 | SDA-2026-04-16-gap-b |
| #91 | TREM2 Conformational Stabilizers for Synaptic Discrimination | TREM2 | 0.685 | $0.57 | sda-2026-04-01-gap-v |
| #92 | Pericyte Contractility Reset via Selective PDGFR-β Agonism | PDGFRB | 0.684 | $0.55 | sda-2026-04-01-gap-v |
| #93 | Multi-Target Synergy via Presynaptic Vesicle Hub Convergence | TH, VMAT2, DAT, GCH1, BDNF, SNCA (presynaptic hub) | 0.683 | $0.58 | SDA-2026-04-13-gap-p |
| #94 | Astrocyte-Selective APOE4 Silencing via Lipid Nanoparticles | APOE4 | 0.682 | $0.58 | SDA-2026-04-03-gap-d |
| #95 | Context-Dependent CRISPR Activation in Specific Neuronal Subtypes | Cell-type-specific essential genes | 0.682 | $0.55 | SDA-2026-04-03-gap-c |
| #96 | HDAC6 Activation as SCFA-Mediated Neuroprotective Mechanism | HDAC6, HSP90AA1 | 0.682 | $0.57 | SDA-2026-04-12-gap-d |
| #97 | Flotillin-1 Stabilization Compounds | FLOT1 | 0.681 | $0.54 | SDA-2026-04-01-gap-l |
| #98 | NLRP3/Mitophagy Coupling Modulation | NLRP3 | 0.681 | $0.57 | SDA-2026-04-03-gap-i |
| #99 | Chaperone-Mediated APOE4 Refolding Enhancement | HSPA1A, HSP90AA1, DNAJB1, FKBP5 | 0.680 | $0.56 | sda-2026-04-01-gap-0 |
| #100 | Osmotic Gradient Restoration via Selective AQP1 Enhancement in Choroid Plexus | AQP1 | 0.680 | $0.55 | sda-2026-04-01-gap-v |
| #101 | Bacterial Tyramine–Induced DOPAL Accumulation in Enteric Neurons | TyrDC (bacterial), ALDH1A1, MAOB, SLC6A3 (DAT) | 0.680 | $0.59 | sda-2026-04-01-gap-2 |
| #102 | Astrocytic Connexin-43 Upregulation Enhances Neuroprotective Mitochondrial Donation | GJA1 | 0.679 | $0.52 | SDA-2026-04-01-gap-2 |
| #103 | White Matter Oligodendrocyte Protection via CXCL10 Inhibition | CXCL10 | 0.675 | $0.58 | SDA-2026-04-03-gap-a |
| #104 | RAB27A-dependent extracellular vesicle engineering for mitochondrial cargo delivery | RAB27A | 0.674 | $0.53 | sda-2026-04-01-gap-v |
| #105 | Metabolic Reprogramming via Microglial Glycolysis Inhibition | HK2 | 0.672 | $0.56 | sda-2026-04-01-gap-v |
| #106 | Partial Neuronal Reprogramming via Modified Yamanaka Cocktail | OCT4 | 0.672 | $0.56 | SDA-2026-04-04-gap-e |
| #107 | OPTN/TBK1 mutations create selective vulnerability by blocking PINK1-Parkin-independent mitophagy in lower motor neurons | OPTN | 0.670 | $0.59 | SDA-2026-04-08-gap-p |
| #108 | Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication | CHRNA7 | 0.669 | $0.55 | SDA-2026-04-01-gap-2 |
| #109 | Mitochondrial-Lysosomal Contact Site Engineering | RAB7A | 0.668 | $0.55 | sda-2026-04-01-gap-0 |
| #110 | Lipid Droplet Dynamics as Phenotype Switches | DGAT1 and SOAT1 | 0.666 | $0.56 | sda-2026-04-01-gap-0 |
| #111 | GAP43-mediated tunneling nanotube stabilization enhances neuroprotective mitochondrial transfer | GAP43 | 0.666 | $0.57 | sda-2026-04-01-gap-v |
| #112 | LRRK2 Volume Sensor Hijacking Drives Metabolic Dysregulation via SIRT1/PGC1α Suppression | LRRK2 | 0.666 | $0.59 | SDA-2026-04-16-gap-p |
| #113 | Complement C1q Subtype Switching | C1QA | 0.665 | $0.57 | sda-2026-04-01-gap-0 |
| #114 | RNA Granule Nucleation Site Modulation | G3BP1 | 0.662 | $0.58 | sda-2026-04-01-gap-0 |
| #115 | PARP1 Inhibition Blocks Poly(PR)-Triggered DNA Damage and Subsequent p53 Activation | PARP1 | 0.661 | $0.57 | SDA-2026-04-15-gap-p |
| #116 | Biorhythmic Interference via Controlled Sleep Oscillations | GABRA1 | 0.661 | $0.56 | sda-2026-04-01-gap-0 |
| #117 | Mitochondrial RNA Granule Rescue Pathway | SYNCRIP | 0.656 | $0.55 | sda-2026-04-01-gap-v |
| #118 | Optogenetic Microglial Deactivation via Engineered Inhibitory Opsins | CX3CR1 | 0.655 | $0.56 | sda-2026-04-01-gap-v |
| #119 | Microbial Inflammasome Priming Prevention | NLRP3, CASP1, IL1B, PYCARD | 0.653 | $0.66 | SDA-2026-04-01-gap-2 |
| #120 | Nucleolar Stress Response Normalization | NPM1 | 0.653 | $0.56 | sda-2026-04-01-gap-v |
| #121 | The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction | TFEB | 0.652 | $0.54 | SDA-2026-04-02-gap-v |
| #122 | Microbiota-Microglia Axis Modulation | Multiple | 0.651 | $0.54 | SDA-2026-04-04-gap-2 |
| #123 | Astrocyte APOE4-Specific Lipid Metabolism Correction | APOE | 0.651 | $0.56 | SDA-2026-04-03-gap-s |
| #124 | Mitochondrial Calcium Buffering Enhancement via MCU Modulation | MCU | 0.650 | $0.55 | sda-2026-04-01-gap-0 |
| #125 | Apoptosis-Senescence Decision Point Intervention | TP53,BAX,BAK1,CASP3 | 0.649 | $0.57 | SDA-2026-04-04-gap-s |
| #126 | DNMT1-Targeting Antisense Oligonucleotide Reset | DNMT1 | 0.648 | $0.55 | sda-2026-04-01-gap-v |
| #127 | HCN1-Mediated Resonance Frequency Stabilization Therapy | HCN1 | 0.648 | $0.54 | sda-2026-04-01-gap-0 |
| #128 | Mitochondrial SPM Synthesis Platform Engineering | ALOX5 | 0.647 | $0.53 | sda-2026-04-01-gap-0 |
| #129 | Epigenetic Reprogramming of Microglial Memory | DNMT3A, HDAC1/2 | 0.647 | $0.57 | SDA-2026-04-04-gap-2 |
| #130 | Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancement | IDH2 | 0.646 | $0.55 | sda-2026-04-01-gap-0 |
| #131 | Synthetic Biology Rewiring via Orthogonal Receptors | CNO | 0.645 | $0.56 | sda-2026-04-01-gap-0 |
| #132 | Ephrin-B2/EphB4 Axis Manipulation | EPHB4 | 0.645 | $0.55 | sda-2026-04-01-gap-0 |
| #133 | Dual Calpain/Cathepsin B Inhibition as Primary Neuroprotective Strategy | - | 0.644 | $0.56 | SDA-2026-04-15-gap-p |
| #134 | Cell-Type Specific Metabolic Reprogramming | PPARA | 0.643 | $0.54 | SDA-2026-04-03-gap-s |
| #135 | TREM2-Mediated Mitochondrial Dysfunction in Neurodegeneration | TREM2 | 0.642 | $0.54 | SDA-2026-04-03-gap-a |
| #136 | Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding | CSGA | 0.642 | $0.54 | SDA-2026-04-01-gap-2 |
| #137 | Colonic Th17/IL-17A Axis → Peripheral Immune Recruitment to SN and Neuronal Apoptosis | RORC (RORγt), IL17A, IL17RA, IL17RC, CXCL9, CXCL10, CXCR3, CD8A | 0.640 | $0.57 | sda-2026-04-01-gap-2 |
| #138 | Heterogeneous astrocyte activation states differentially impact neuronal survival across AD progression | GFAP | 0.640 | $0.55 | SDA-2026-04-04-analy |
| #139 | Transglutaminase-2 Cross-Linking Inhibition Strategy | TGM2 | 0.639 | $0.56 | SDA-2026-04-01-gap-9 |
| #140 | Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention for Severe Neurodevelopmental Forms | SOD1, HTT, TARDBP | 0.638 | $0.56 | SDA-2026-04-03-gap-c |
| #141 | TREM2-Dependent Microglial Phagocytosis Acts as a Strain Selection Filter | TREM2 | 0.636 | $0.58 | SDA-2026-04-15-gap-d |
| #142 | HSP90-Tau Disaggregation Complex Enhancement | HSP90AA1 | 0.634 | $0.61 | SDA-2026-04-04-gap-t |
| #143 | Palmitoylethanolamide-Based Endocannabinoid Therapy | PPARA | 0.633 | $0.54 | SDA-2026-04-16-gap-b |
| #144 | TREM2 R47H Variant Correction — AAV-Mediated Rescue of Common Risk Allele | TREM2 | 0.631 | $0.57 | SDA-2026-04-02-gap-0 |
| #145 | Disease-Associated Microglia Metabolic Reprogramming | TREM2 | 0.631 | $0.57 | SDA-2026-04-03-gap-s |
| #146 | FOXO3-Longevity Pathway Epigenetic Reprogramming | FOXO3 | 0.630 | $0.55 | sda-2026-04-01-gap-v |
| #147 | Intestinal Permeability Defects → Systemic LPS Translocation → Microglial Priming | Tight junction complex (CLDN1, OCLN, TJP1), LBP, CD14, TLR4, MYD88, NFKB1 | 0.630 | $0.57 | sda-2026-04-01-gap-2 |
| #148 | Programmable Neuronal Circuit Repair via Epigenetic CRISPR | NURR1, PITX3, neuronal identity transcription factors | 0.630 | $0.52 | SDA-2026-04-03-gap-c |
| #149 | Autophagosome-Lysosome Fusion Defects as Primary Driver of α-Synuclein Propagation | VPS41, STX17, HOPS complex, TRPML1 (MCOLN1) | 0.630 | $0.57 | SDA-2026-04-02-gap-2 |
| #150 | Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring | Disease-causing mutations with integrated reporters | 0.629 | $0.52 | SDA-2026-04-03-gap-c |
| #151 | Quantum Coherence Disruption in Cellular Communication | TUBB3 | 0.627 | $0.54 | sda-2026-04-01-gap-0 |
| #152 | Peripheral-to-Central Inflammation Circuit Breaker | IL1B | 0.626 | $0.57 | SDA-2026-04-16-gap-b |
| #153 | Heat Shock Protein 70 Disaggregase Amplification | HSPA1A | 0.625 | $0.56 | sda-2026-04-01-gap-0 |
| #154 | Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics | ANXA1 | 0.625 | $0.54 | sda-2026-04-01-gap-v |
| #155 | Autophagy-Senescence Axis Therapeutic Window | ATG7,BCL2,BCL2L1 | 0.624 | $0.58 | SDA-2026-04-04-gap-s |
| #156 | TFEB-PGC1α Mitochondrial-Lysosomal Decoupling | TFEB | 0.622 | $0.53 | SDA-2026-04-03-gap-a |
| #157 | Cholesterol-CRISPR Convergence Therapy for Neurodegeneration | HMGCR, LDLR, APOE regulatory regions | 0.622 | $0.54 | SDA-2026-04-03-gap-c |
| #158 | Pharmacological Enhancement of APOE4 Glycosylation | ST6GAL1, FUT8 | 0.622 | $0.52 | sda-2026-04-01-gap-0 |
| #159 | Vagal Afferent Microbial Signal Modulation | GLP1R, BDNF | 0.621 | $0.55 | SDA-2026-04-01-gap-2 |
| #160 | Cross-Cell Type Synaptic Rescue via Tripartite Synapse Restoration | SYN1, SLC1A2, and CX3CR1 | 0.620 | $0.56 | SDA-2026-04-03-gap-s |
| #161 | H7: Enteric Nervous System Alpha-Synuclein Propagation Blocker via Gut Barrier Restoration | IL-22, REG3G, zonulin | 0.620 | $0.60 | SDA-2026-04-15-gap-p |
| #162 | BH4 Cofactor Restoration as Primary Driver of >500-Fold Dopamine Elevation | GCH1, TH, BH4 pathway | 0.618 | $0.54 | SDA-2026-04-13-gap-p |
| #163 | TREM2-mediated microglial tau clearance enhancement | TREM2 | 0.618 | $0.67 | SDA-2026-04-04-gap-t |
| #164 | Dose-Response Framework: PINK1/Parkin Mitophagy as the Critical Mediator Linking HBOT Parameters to Tau Clearance | PINK1 | 0.614 | $0.56 | SDA-2026-04-26-gap-p |
| #165 | Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuroinflammatory Cascade | AGER | 0.613 | $0.52 | SDA-2026-04-01-gap-2 |
| #166 | Restoring Neuroprotective Tryptophan Metabolism via Targeted Probiotic Engineering | TDC | 0.612 | $0.53 | SDA-2026-04-01-gap-2 |
| #167 | SIRT6-NAD+ Axis Enhancement Therapy | SIRT6 | 0.612 | $0.54 | sda-2026-04-01-gap-v |
| #168 | Synaptic Pruning Precision Therapy | C1QA, C3, CX3CR1, CX3CL1 | 0.612 | $0.57 | SDA-2026-04-04-gap-2 |
| #169 | Age-Accelerated miR-155 Upregulation Primes Nigral Microglia for Parkinson's Disease Pathology | miR-155 | 0.610 | $0.56 | SDA-2026-04-06-gap-p |
| #170 | The Glial Ketone Metabolic Shunt Hypothesis | HMGCS2 | 0.608 | $0.55 | SDA-2026-04-02-gap-v |
| #171 | Correcting Gut Microbial Dopamine Imbalance to Support Systemic Dopaminergic Function | DDC | 0.606 | $0.52 | SDA-2026-04-01-gap-2 |
| #172 | TREM2-Microglial Clearance Enhancement as Common Mechanism for Injury Prevention | TREM2 | 0.604 | $0.58 | SDA-2026-04-14-gap-p |
| #173 | Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits | PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes | 0.599 | $0.52 | SDA-2026-04-03-gap-c |
| #174 | Glycosaminoglycan Template Disruption Approach | HSPG2 | 0.597 | $0.53 | SDA-2026-04-01-gap-9 |
| #175 | Netrin-1 Gradient Restoration | NTN1 | 0.595 | $0.54 | sda-2026-04-01-gap-0 |
| #176 | VCP-Mediated Autophagy Enhancement | VCP | 0.595 | $0.64 | SDA-2026-04-04-gap-t |
| #177 | AP1S1-Mediated Vesicular Transport Restoration | AP1S1 | 0.588 | $0.54 | SDA-2026-04-03-gap-a |
| #178 | Cardiovascular-Neuroinflammation Crosstalk Interruption | IL1B, TNFA, NLRP3 | 0.587 | $0.56 | SDA-2026-04-04-gap-2 |
| #179 | TNFRSF25-Mediated Aging Exosome Pathway Inhibition | TNFRSF25 | 0.587 | $0.54 | SDA-2026-04-03-gap-a |
| #180 | TREM2-Mediated Selective Aggregate Clearance Pathway | TREM2 | 0.584 | $0.52 | SDA-2026-04-01-gap-9 |
| #181 | IGFBPL1-Mediated Homeostatic Restoration | IGFBPL1 | 0.584 | $0.56 | SDA-2026-04-04-gap-2 |
| #182 | Extracellular Vesicle Biogenesis Modulation | CHMP4B | 0.582 | $0.58 | SDA-2026-04-04-gap-t |
| #183 | HSP90-Tau Disaggregation Complex Enhancement | HSP90AA1 | 0.575 | $0.74 | SDA-2026-04-04-gap-t |
| #184 | PINK1/PARK2-Mediated Mitophagy Enhancement for Neuroinflammation Control | PINK1 | 0.571 | $0.55 | SDA-2026-04-03-gap-i |
| #185 | Neuronal Subtype-Specific Alpha-Synuclein Expression Normalization | SNCA | 0.571 | $0.55 | SDA-BIOMNI-BINDER_D- |
| #186 | CX43 hemichannel engineering enables size-selective mitochondrial transfer | GJA1 | 0.566 | $0.55 | sda-2026-04-01-gap-v |
| #187 | Vascular-Glial Interface Restoration | CLDN5 | 0.566 | $0.54 | SDA-2026-04-03-gap-s |
| #188 | Astroglial Gap Junction Coordination via Connexin-43 Phosphorylation Modulation | GJA1 | 0.566 | $0.58 | sda-2026-04-01-gap-v |
| #189 | Temporal Gating of Microglial Responses | CLOCK, ARNTL | 0.565 | $0.54 | SDA-2026-04-04-gap-2 |
| #190 | Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators | CX3CR1 | 0.563 | $0.53 | sda-2026-04-01-gap-v |
| #191 | TRPML1-PINK1/Parkin Axis Coordinates Mitophagy with Lysosomal Biogenesis | MCOLN1, PINK1, PARK2, TFEB, LRRK2 | 0.560 | $0.55 | SDA-2026-04-16-gap-d |
| #192 | AMPK Activation to Restore Autophagy and Clear α-Synuclein Aggregates | - | 0.559 | $0.53 | SDA-2026-04-17-gap-p |
| #193 | Circadian-Gated Maresin Biosynthesis Amplification | ALOX12 | 0.557 | $0.56 | sda-2026-04-01-gap-0 |
| #194 | Gut-Brain Axis Microbiome Modulation | GPR43, GPR109A | 0.557 | $0.54 | SDA-2026-04-04-gap-2 |
| #195 | Inhibitory Neuron-Selective WNT Signaling Restoration | WNT3A, CTNNB1, TCF7L2 | 0.554 | $0.53 | SDA-2026-04-03-gap-d |
| #196 | Profilin-1 Cytoskeletal Checkpoint Enhancement | PFN1 | 0.554 | $0.53 | SDA-2026-04-03-gap-a |
| #197 | Dual NF-κB/MMP Inhibition Strategy | NFKB1 | 0.554 | $0.55 | SDA-2026-04-16-gap-b |
| #198 | P2RX7-Mediated Exosome Secretion Blockade | P2RX7 | 0.552 | $0.57 | SDA-2026-04-04-gap-t |
| #199 | Liquid-Liquid Phase Separation Modifier Therapy | G3BP1 | 0.551 | $0.53 | SDA-2026-04-01-gap-9 |
| #200 | Digital Twin-Guided Metabolic Reprogramming | PPARGC1A/PRKAA1 | 0.550 | $0.54 | sda-2026-04-01-gap-0 |
| #201 | Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy | RHOT1 | 0.549 | $0.51 | SDA-2026-04-01-gap-2 |
| #202 | Multi-Chaperone System Co-Activation Prevents Saturation Through Complementary Substrate Recognition | DNAJB1, HSP90AA1/HSP90AB1, STIP1 (HOP) | 0.549 | $0.54 | SDA-2026-04-06-gap-d |
| #203 | Sensory-Motor Circuit Cross-Modal Compensation | CHAT | 0.546 | $0.51 | SDA-2026-04-03-26abc |
| #204 | CD300f Immune Checkpoint Activation | CD300F | 0.545 | $0.53 | SDA-2026-04-03-gap-a |
| #205 | Trans-Synaptic Adhesion Molecule Modulation | NLGN1 | 0.544 | $0.53 | SDA-2026-04-04-gap-t |
| #206 | HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor | DNAJB6 | 0.544 | $0.51 | SDA-2026-04-01-gap-9 |
| #207 | Temporal Decoupling via Circadian Clock Reset | CLOCK | 0.543 | $0.58 | sda-2026-04-01-gap-0 |
| #208 | Lysosomal Membrane Repair Enhancement | CHMP2B | 0.538 | $0.56 | sda-2026-04-01-gap-0 |
| #209 | Glymphatic System-Enhanced Antibody Clearance Reversal | AQP4 | 0.537 | $0.58 | sda-2026-04-01-gap-0 |
| #210 | Blood-Brain Barrier SPM Shuttle System | TFRC | 0.533 | $0.57 | sda-2026-04-01-gap-0 |
| #211 | Gut Barrier Permeability-α-Synuclein Axis Modulation | CLDN1, OCLN, ZO1, MLCK | 0.533 | $0.53 | SDA-2026-04-01-gap-2 |
| #212 | EV-Mediated Epigenetic Reprogramming | EVs/miRNAs | 0.532 | $0.53 | sda-2026-04-12-ev-ad |
| #213 | Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioenergetics | SLC16A2 | 0.529 | $0.55 | sda-2026-04-01-gap-0 |
| #214 | PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria | BNIP3/BNIP3L | 0.529 | $0.51 | SDA-2026-04-01-gap-2 |
| #215 | Piezoelectric Nanochannel BBB Disruption | CLDN5, OCLN | 0.519 | $0.53 | sda-2026-04-01-gap-0 |
| #216 | NRF2 Activation to Counteract Oxidative Stress from RGS6 Deficiency | - | 0.518 | $0.51 | SDA-2026-04-17-gap-p |
| #217 | Membrane interfacial selectivity for lipid-anchored pathologic conformers | SNCA, HSPA8, DNAJB6 | 0.518 | $0.52 | SDA-2026-04-10-gap-d |
| #218 | Vocal Cord Neuroplasticity Stimulation | CHR2/BDNF | 0.515 | $0.54 | sda-2026-04-01-gap-0 |
| #219 | EV-Mediated Epigenetic Reprogramming | EVs/miRNAs | 0.513 | $0.60 | sda-2026-04-12-ev-ad |
| #220 | Microbial Metabolite-Mediated α-Synuclein Disaggregation | SNCA, HSPA1A, DNMT1 | 0.511 | $0.52 | SDA-2026-04-01-gap-2 |
| #221 | Synthetic Biology Approach: Designer Mitochondrial Export Systems | Synthetic fusion proteins | 0.505 | $0.51 | SDA-2026-04-01-gap-2 |
| #222 | Trans-Synaptic Adhesion Molecule Modulation | NLGN1 | 0.503 | $0.55 | SDA-2026-04-04-gap-t |
| #223 | Selectively Inhibit Maladaptive AQP4-Driven Astrocyte-Microglia Inflammatory Signaling in Parkinsonian Injury | AQP4, NFKB1, IL1B, TNF | 0.500 | $0.52 | SDA-2026-04-07-gap-p |
| #224 | Conditional CRISPR Kill Switches for Aberrant Protein Clearance | UBE3A, PARK2, PINK1 | 0.496 | $0.60 | SDA-2026-04-03-gap-c |
| #225 | Temporal NLRP3 Inhibition via SPP1-Mediated Mitophagy Enhancement During Critical Neuroinflammatory Windows | NLRP3 | 0.496 | $0.52 | SDA-2026-04-15-gap-p |
| #226 | Testosterone-Derived DHT Amplifies Microglial Androgen Receptor Signaling Driving Male-Biased Neuroinflammation | AR | 0.490 | $0.51 | SDA-2026-04-06-gap-p |
| #227 | PINK1/PARK2-LC3 Mitophagy Enhancement | PINK1 | 0.485 | $0.50 | SDA-2026-04-03-gap-i |
| #228 | Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery | RAB27A/LAMP2B | 0.482 | $0.47 | SDA-2026-04-01-gap-2 |
| #229 | Isoform-Selective Hsp70 Targeting Overcomes Stoichiometric Imbalance in Advanced Pathology | HSPA1A, DNAJB6, DNAJB8 | 0.481 | $0.53 | SDA-2026-04-06-gap-d |
| #230 | Enteric Nervous System Prion-Like Propagation Blockade | TLR4, SNCA | 0.480 | $0.48 | SDA-2026-04-01-gap-2 |
| #231 | Optogenetic Control of Mitochondrial Transfer Networks | ChR2 | 0.476 | $0.47 | SDA-2026-04-01-gap-2 |
| #232 | Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption | PHB2 | 0.469 | $0.46 | SDA-2026-04-01-gap-9 |
| #233 | Cross-Tissue Communication Disruption | MULTIPLE | 0.466 | $0.51 | SDA-2026-04-16-gap-b |
| #234 | RNA-Binding Competition Therapy for TDP-43 Cross-Seeding | TARDBP | 0.465 | $0.45 | SDA-2026-04-01-gap-9 |
| #235 | Mitochondrial Dysfunction in Neurodegeneration | NDUFV1 | 0.460 | $0.00 | - |
| #236 | DNMT3A-Mediated de novo Methylation Corrects 'Epigenetic Scars' at Polycomb Targets | DNMT3A | 0.460 | $0.53 | SDA-2026-04-10-gap-2 |
| #237 | Selective Microglial Senescence Targeting via TREM2 Modulation | TREM2 | 0.459 | $0.52 | SDA-2026-04-04-gap-s |
| #238 | PGC1α Activation in PV+ Interneurons Bypasses Mitophagy Deficit to Restore Gamma Oscillations | PPARGC1A | 0.455 | $0.50 | SDA-2026-04-15-gap-p |
| #239 | C1q Inhibition Prevents Synaptic Mitochondrial Dysfunction via Microglial-Neuronal Cross-Talk Normalization | C1QA/C1QB/C1QC | 0.455 | $0.49 | SDA-2026-04-15-gap-p |
| #240 | Metabolic Reprogramming Toward GAPDH Inhibition | GAPDH, HK2 | 0.450 | $0.52 | SDA-2026-04-07-gap-p |
| #241 | GSK3β Inhibition to Prevent α-Synuclein Phosphorylation and Aggregation | - | 0.429 | $0.47 | SDA-2026-04-17-gap-p |
| #242 | Microbiome-Derived Tryptophan Metabolite Neuroprotection | AHR, IL10, TGFB1 | 0.427 | $0.45 | SDA-2026-04-01-gap-2 |
| #243 | AAV-Mediated RGS6 Overexpression in Substantia Nigra Parvocellular Neurons | - | 0.424 | $0.49 | SDA-2026-04-17-gap-p |
| #244 | IGFBPL1 Peptide Mimetics for Drug-Like BBB Permeability | IGFBPL1 | 0.397 | $0.51 | SDA-2026-04-06-gap-d |
| #245 | Bacterial Enzyme-Mediated Dopamine Precursor Synthesis | TH, AADC | 0.384 | $0.44 | SDA-2026-04-01-gap-2 |
| #246 | Hippocampal mitochondrial dysfunction accelerates with age and drives regional AD vulnerability | TFAM | 0.374 | $0.53 | aging-mouse-brain-20 |
| #247 | Gap Junction Hemichannel Modulation for Controlled Mitochondrial Exchange | PANX1 | 0.361 | $0.44 | SDA-2026-04-01-gap-2 |
| #248 | D2 Autoreceptor Partial Agonism as Compensatory Therapy for RGS6 Deficiency | - | 0.348 | $0.44 | SDA-2026-04-17-gap-p |
| #249 | Combination Gene Therapy Targeting RGS6 and Parkin or PINK1 to Address Mitochondrial Dysfunction | PINK1 | 0.317 | $0.45 | SDA-2026-04-17-gap-p |
| #250 | [Archived Hypothesis] | - | 0.300 | $0.30 | legacy-pre-pipeline- |
| #251 | PDE10A Inhibition to Bypass RGS6 Deficiency via cAMP Pathway Normalization | - | 0.224 | $0.42 | SDA-2026-04-17-gap-p |
| #252 | P2RX7-PANX1 Channel Blockade for Neuroinflammatory Cascade Interruption | - | 0.105 | $0.42 | SDA-NEUROINFLAM-BIOM |